{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:32:26Z","timestamp":1724077946211},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the medical records of 22 patients admitted with rhabdomyolysis associated with fenoverine from January 1999 to December 2014, while excluding other well-known risk factors of rhabdomyolysis. This period was subdivided into two periods, January 1999\u2013December 2007 and January 2008\u2013December 2014. We analyzed the clinical and laboratory characteristics, and the prognosis of fenoverine associated with rhabdomyolysis for these times.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incidence of rhabdomyolysis associated with fenoverine was 0.27% during the total period (22\/8257), 0.34% in the first period (18\/5298), and 0.14% in the second period (4\/2959) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Rhabdomyolysis occurred in 19 liver cirrhosis (LC) patients (2.03%), whereas only 3 cases (0.04%) occurred in non-LC patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Drug duration, total dose, muscle enzymes, and clinical characteristics were not different between the LC and non-LC groups. Acute renal failure (ARF) occurred in 5 patients in the LC group and 2 patients in the non-LC group (<jats:italic>p<\/jats:italic>\u2009=\u20090.227). Severity of hepatic derangement according to the Child-Pugh classification was not different between the ARF group and non-ARF group (<jats:italic>p<\/jats:italic>\u2009=\u20090.227). Four patients died, having complications of oliguric ARF (<jats:italic>p<\/jats:italic>\u2009=\u20090.005) and underlying severe LC (<jats:italic>p<\/jats:italic>\u2009=\u20090.017). Higher serum lactate dehydrogenase, blood urea nitrogen, creatinine, and potassium levels but lower serum sodium levels were found in the group that died (<jats:italic>p<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Physicians should carefully prescribe fenoverine because it may cause rhabdomyolysis, especially in patients with LC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40360-020-00408-3","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T19:02:56Z","timestamp":1587841376000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999\u20132014)"],"prefix":"10.1186","volume":"21","author":[{"given":"Junhyeong","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeonggu","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Nee","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Seop","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Ho","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"408_CR1","first-page":"907","volume":"65","author":"JM Sauret","year":"2002","unstructured":"Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician. 2002;65:907\u201312.","journal-title":"Am Fam Physician"},{"key":"408_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/mus.10053","volume":"25","author":"JD Warren","year":"2002","unstructured":"Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve. 2002;25:332\u201347.","journal-title":"Muscle Nerve"},{"key":"408_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0749-0704(05)70061-0","volume":"15","author":"P Visweswaran","year":"1999","unstructured":"Visweswaran P, Guntupalli J. Rhabdomyolysis. Crit Care Clin. 1999;15:415\u201328.","journal-title":"Crit Care Clin"},{"key":"408_CR4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1681\/ASN.V1181553","volume":"11","author":"R Vanholder","year":"2000","unstructured":"Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol. 2000;11:1553\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"408_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra0801327","volume":"361","author":"X Bosch","year":"2009","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62\u201372.","journal-title":"N Engl J Med"},{"key":"408_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s001340100878","volume":"27","author":"SG Holt","year":"2001","unstructured":"Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27:803\u201311.","journal-title":"Intensive Care Med"},{"key":"408_CR7","first-page":"316","volume":"2","author":"N Lameire","year":"1987","unstructured":"Lameire N, Matthys E, Vanholder R, De Keyser K, Pauwels W, Nachtergaele H, Lambrecht L, Ringoir S. Causes and prognosis of acute renal failure in elderly patients. Nephrol Dial Transplant. 1987;2:316\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"408_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11739-007-0060-8","volume":"2","author":"WH Bagley","year":"2007","unstructured":"Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2:210\u20138.","journal-title":"Intern Emerg Med"},{"key":"408_CR9","first-page":"272","volume":"67","author":"FY Khan","year":"2009","unstructured":"Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67:272\u201383.","journal-title":"Neth J Med"},{"key":"408_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/bmj.327.7407.115","volume":"327","author":"R Lane","year":"2003","unstructured":"Lane R, Philps M. Rhabdomyolysis has many causes, including statins, and may be fatal. BMJ. 2003;327:115\u20136.","journal-title":"BMJ."},{"key":"408_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00008480-200404000-00017","volume":"16","author":"TJ Coco","year":"2004","unstructured":"Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. Curr Opin Pediatr. 2004;16:206\u201310.","journal-title":"Curr Opin Pediatr"},{"key":"408_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","volume":"12","author":"M Hohenegger","year":"2012","unstructured":"Hohenegger M. Drug-induced rhabdomyolysis. Curr Opin Pharmacol. 2012;12:335\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"408_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1185\/03007998609111090","volume":"10","author":"E Camarri","year":"1986","unstructured":"Camarri E. Fenoverine: smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation. Curr Med Res Opin. 1986;10:52\u20137.","journal-title":"Curr Med Res Opin"},{"key":"408_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1185\/03007998709112400","volume":"10","author":"J Gonella","year":"1987","unstructured":"Gonella J, Lalanne C, Mironneau J. Fenoverine: a novel synchronizer of smooth muscle motility by interference with cellular calcium flow. Curr Med Res Opin. 1987;10:427\u201335.","journal-title":"Curr Med Res Opin"},{"key":"408_CR15","first-page":"861","volume":"15","author":"X H\u00e9buterne","year":"1991","unstructured":"H\u00e9buterne X, Chichmanian RM, Cohen HL, Rampal P. Acute rhabdomyolysis due to fenoverine. Gastroenterol Clin Biol. 1991;15:861\u20132.","journal-title":"Gastroenterol Clin Biol"},{"key":"408_CR16","first-page":"165","volume":"47","author":"JM Hardin","year":"1992","unstructured":"Hardin JM, Guillebaud JC, Lallement PY, Matta B, Andrejak M. Rhabdomyolysis associated to fenoverine therapy and complicated by acute renal failure. Therapie. 1992;47:165\u20136.","journal-title":"Therapie."},{"key":"408_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0248-8663(05)82187-3","volume":"15","author":"H Ouakil","year":"1994","unstructured":"Ouakil H, Pouchot J, Debin ML, Le Bourdelles G, Coste F, Vinceneux P. Acute rhabdomyolysis caused by fenoverine. Rev Med Interne. 1994;15:695\u20136.","journal-title":"Rev Med Interne"},{"key":"408_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1177\/096032719501400805","volume":"14","author":"P Chariot","year":"1995","unstructured":"Chariot P, Ratiney R, Le Maguet F, Fouresti\u00e9 V, Astier A, Gherardi R. Fenoverine-induced rhabdomyolysis. Hum Exp Toxicol. 1995;14:654\u20136.","journal-title":"Hum Exp Toxicol"},{"key":"408_CR19","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1016\/S0248-8663(05)81587-5","volume":"13","author":"RM Chichmanian","year":"1992","unstructured":"Chichmanian RM, Spreux A, Bouillet M, Chiffoleau A, Baudot S, Larousse C. Rhabdomyolyses dues a la fenoverine: analyse de 45 cas. Rev Med Interne. 1992;13:S114.","journal-title":"Rev Med Interne"},{"key":"408_CR20","first-page":"501","volume":"20","author":"SY Park","year":"2001","unstructured":"Park SY, Lee KJ, Song JH, et al. Fenoverine-induced rhabdomyolysis in a patient with liver cirrhosis. Korean J Nephrol. 2001;20:501\u20135.","journal-title":"Korean J Nephrol"},{"key":"408_CR21","first-page":"465","volume":"62","author":"KH Kim","year":"2002","unstructured":"Kim KH, Sim MR, Kye YH, et al. A case of fenoverine-induced rhabdomyolysis in diabetic nephropathy. Korean J Med. 2002;62:465\u20138.","journal-title":"Korean J Med"},{"key":"408_CR22","first-page":"680","volume":"24","author":"KR Na","year":"2005","unstructured":"Na KR, Jeong S, Jang DS, et al. 3 cases of Fenoverine-induced rhabdomyolysis. Korean J Nephrol. 2005;24:680\u20135.","journal-title":"Korean J Nephrol"},{"issue":"1","key":"408_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","volume":"20","author":"LO Chavez","year":"2016","unstructured":"Chavez LO, Leon M, Einav S, Varon J. Beyond muscle. Destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135.","journal-title":"Crit Care"},{"key":"408_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/pgmj.69.811.333","volume":"69","author":"BD Prendergast","year":"1993","unstructured":"Prendergast BD, George CF. Drug- induced rhabdomyolysis: mechanisms, and management. Postgrad Med J. 1993;69:333\u20136.","journal-title":"Postgrad Med J"},{"key":"408_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/096032719601501004","volume":"15","author":"J Jouglard","year":"1996","unstructured":"Jouglard J, Kozak-Ribbens G, de Haro L, Cozzone PJ. Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine. Hum Exp Toxicol. 1996;15:815\u201320.","journal-title":"Hum Exp Toxicol"},{"key":"408_CR26","first-page":"810","volume":"13","author":"HY Kim","year":"1994","unstructured":"Kim HY, Choi OS, Shin SJ, et al. Analysis of 250 cases of rhabdomyolysis. Korean J Nephrol. 1994;13:810\u20137.","journal-title":"Korean J Nephrol"},{"key":"408_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00005792-198205000-00002","volume":"61","author":"PA Gabow","year":"1982","unstructured":"Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982;61:141\u201352.","journal-title":"Medicine (Baltimore)"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-020-00408-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T08:50:03Z","timestamp":1666428603000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00408-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"3 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We respected all patients\u2019 rights to privacy and protected their identity. The study protocol was approved by the Institutional Review Board of Gyeongsang National University Hospital (IRB no. 2013\u201303-018), who waived the need for informed consent. All individual information was deidentified.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}